

RETENSION PHARMACEUTICALS, INC.

Filed by
B GROUP, INC.

FORM SC 13G (Statement of Ownership)

Filed 10/16/26

Address	C/O REDUX THERAPEUTICS, LLC 902 TURKEY RUN ROAD MCLEAN, VA, 22101
Telephone	(703) 624-2024
CIK	0002002988
Symbol	RTSN
SIC Code	2834 - Pharmaceutical Preparations
Fiscal Year	12/31

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Retension Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value

(Title of Class of Securities)

76135H100

(CUSIP Numbers)

10/13/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP Number(s): 76135H100

1	Names of Reporting Persons The B Group, Inc.
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)
3	SEC Use Only

4	Citizenship or Place of Organization KANSAS	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power: 0.00
	6	Shared Voting Power: 833,333.00
	7	Sole Dispositive Power: 0.00
	8	Shared Dispositive Power: 833,333.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 833,333.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 10.00 %	
12	Type of Reporting Person (See Instructions) IA, HC	

SCHEDULE 13G

CUSIP Number(s):	76135H100
------------------	-----------

1	Names of Reporting Persons B Group Capital LLC	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	SEC Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power: 0.00
	6	Shared Voting Power: 833,333.00
	7	Sole Dispositive Power: 0.00
	8	Shared Dispositive Power: 833,333.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 833,333.00	
	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	

10	☐
11	Percent of class represented by amount in row (9) 10.00 %
12	Type of Reporting Person (See Instructions) OO

SCHEDULE 13G

CUSIP Number(s):	76135H100
---------------------	-----------

1	Names of Reporting Persons Branden B. Muhl	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	SEC Use Only	
4	Citizenship or Place of Organization UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power: 0.00
	6	Shared Voting Power: 833,333.00
	7	Sole Dispositive Power: 0.00
	8	Shared Dispositive Power: 833,333.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 833,333.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 10.00 %	
12	Type of Reporting Person (See Instructions) HC, IN	

SCHEDULE 13G

(a) Name of issuer:

Retention Pharmaceuticals, Inc.

(b) Address of issuer's principal executive offices:

1104 West Broad Street #1029, Falls Church, Virginia 22046

Item 2.

(a) Name of person filing:

Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of:

The B Group, Inc.
B Group Capital LLC
Branden B. Muhl

The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

(b) Address or principal business office or, if none, residence:

The principal business address of The B Group, Inc. is 2900 McKinnon Street, Suite 1101, Dallas, Texas 75201.

The principal business address of each of B Group Capital LLC and Mr. Muhl is c/o The B Group, Inc., 2900 McKinnon Street, Suite 1101, Dallas, Texas 75201.

(c) Citizenship:

The B Group, Inc. is organized under the laws of the State of Kansas.

B Group Capital LLC is organized under the laws of the State of Delaware.

Branden B. Muhl is a citizen of the United States.

(d) Title of class of securities:

Common Stock, \$0.0001 par value

(e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

(a) **Amount beneficially owned:**

The information required by Item 4(a) is set forth in Row 9 of the cover page for each Reporting Person and is incorporated herein by reference.

This Schedule 13G relates to 833,333 shares of Common Stock held by B Group Capital LLC. The B Group, Inc. serves as investment adviser to B Group Capital LLC. Mr. Muhl is the controlling person and manager of The B Group, Inc. and B Group Capital LLC, respectively. In such capacities, The B Group, Inc. and Mr. Muhl may each be deemed to beneficially own the shares of Common Stock held by B Group Capital LLC.

(b) **Percent of class:**

The information required by Item 4(b) is set forth in Row 11 of the cover page for each Reporting Person and is incorporated herein by reference.

Ownership percentages are based on 8,331,599 shares of the Issuer's Common Stock outstanding immediately after giving effect to the completion of the Issuer's initial public offering, as reported in the Prospectus Supplement filed pursuant to Rule 424(b)(4) by the Issuer with the Securities and Exchange Commission on October 9, 2026.

(c) **Number of shares as to which the person has:**

(i) **Sole power to vote or to direct the vote:**

The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each Reporting Person and is incorporated herein by reference.

(ii) **Shared power to vote or to direct the vote:**

The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each Reporting Person and is incorporated herein by reference.

(iii) **Sole power to dispose or to direct the disposition of:**

The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each Reporting Person and is incorporated herein by reference.

(iv) **Shared power to dispose or to direct the disposition of:**

The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each Reporting Person and is incorporated herein by reference.

Item 5. Ownership of 5 Percent or Less of a Class.

Not Applicable

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of

or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The B Group, Inc.

Signature: /s/ **Branden B. Muhl**
Name/Title: **Branden B. Muhl/Chief Executive Officer**
Date: **10/16/2026**

B Group Capital LLC

Signature: /s/ **Branden B. Muhl**
Name/Title: **Branden B. Muhl/Manager**
Date: **10/16/2026**

Branden B. Muhl

Signature: /s/ **Branden B. Muhl**
Name/Title: **Branden B. Muhl**
Date: **10/16/2026**

Exhibit Information: [Exhibit 99: Joint Filing Agreement](#)

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of the 16th day of October 2026.

The B Group, Inc.

By: /s/ Branden B. Muhl

Name: Branden B. Muhl

Title: Chief Executive Officer

B Group Capital LLC

By: /s/ Branden B. Muhl

Name: Branden B. Muhl

Title: Manager

Branden B. Muhl

By: /s/ Branden B. Muhl